Intervet’s equine West Nile vaccine approved by USDA

14 September 2006

Arnhem, the Netherlands

An equine vaccine developed by Akzo Nobel’s animal health business Intervet, which is indicated for use in horses at risk from West Nile virus has been approved by the United States Department of Agriculture (USDA) for use in the United States.

PreveNileTM is the first one-dose modified-live virus vaccine to be registered in the United States for the prevention of viremia (the presence of a virus in the blood) caused by West Nile virus (WNV) infection in horses. 

The virus—which can also be contracted by humans—is primarily spread by mosquitoes. In 2002 an outbreak in the United States seriously affected the horse population, as well as killing almost 300 people.

“We are quite excited about what this new technology can offer in terms of enhanced efficacy against this life-threatening disease in horses,” said Intervet General Manager Ruurd Stolp. “In challenge studies, 100 percent of vaccinated horses were protected from fever and the presence of virus in the bloodstream.”

In 2005, there were 1,075 reported cases of equine WNV in the United States. Since 1999, more than 30 percent of the cases of WNV diagnosed in horses have resulted in death. 

Infection does not always lead to signs of illness in people or animals, but horses are susceptible to contracting the disease. In horses that do become clinically ill, the virus infects the central nervous system and may cause symptoms of encephalitis (inflammation of the brain).

“As the world’s largest animal vaccine producer, Intervet is continually striving to develop innovative drugs for the global animal health market,” added Stolp. “PreveNile is the latest in a series of significant products to have emerged from our strong pipeline.”

Commonly found in Africa, west Asia and the Middle East, WNV has spread to the Caribbean and Latin America via infected mosquitoes and birds. The disease was unknown in the Americas until 1999, when an outbreak killed seven people in New York.

Approval for PreveNile—the only one-dose USDA-approved equine WNV vaccine—comes just days after Intervet was granted an EU license for its Nobilis Influenza H5N2 vaccine, which protects birds against the current H5N1 field strain of avian flu.

- - -

Note for the editor
Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 62,440 people and conduct our activities in four segments − human and animal health, coatings and chemicals − subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the third quarter will be published on October 18, 2006. 

Internet: www.akzonobel.com

Not for publication – for more information
Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43
Contact: Patricia Janssen

Safe Harbor Statement*
This press release may contain statements which address such key issues as Akzo Nobel’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company’s corporate website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.